Zymeworks
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 277
- Market Cap
- $822M
- Introduction
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030
The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171
Zymeworks Inc. initiates Phase 1 trial for ZW171, a T cell engager targeting mesothelin-expressing cancers like ovarian and non-small cell lung cancer, aiming to improve tolerability and efficacy.
Related Clinical Trials:
Bispecific Antibody Drug Conjugates Market Opportunity
The Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029 report highlights the potential of BsADCs to transform cancer treatment. With over 60 drug conjugates in clinical trials, China leads with more than 35 candidates. Key companies like Amgen, Innovent Biologics, and AstraZeneca are pioneering BsADC development. The market is expected to grow significantly, driven by advancements in antibody engineering and rising R&D investments.
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on ...
Zymeworks Inc. to report Q3 2024 financial results on Oct 31, 2024, followed by a conference call at 4:30 pm ET. Zanidatamab, a HER2-targeted bispecific antibody, is under evaluation in global clinical trials and has BLA submissions accepted by the FDA and NMPA for Priority Review.
Two decades of advances in clinical oncology — lessons learned and future directions
S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3
S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks
Zevra Therapeutics Inc. (ZVRA) received FDA approval for MIPLYFFA in treating Niemann-Pick disease type C, driving its shares to a 52-week high. Other stocks also reached new highs, with Arcellx Inc. (ACLX) showing a 596% gain.
Recent Breakthroughs in Cancer Research Could Impact These Key Companies
Recent cancer research breakthroughs include Oncolytics Biotech's BRACELET-1 study showing promising results for pelareorep in HR+/HER2- breast cancer, Novartis AG's FDA approval of Kisqali for early-stage breast cancer, Lantheus Holdings' positive Phase 3 SPLASH trial results for 177Lu-PNT2002 in prostate cancer, Sutro Biopharma's encouraging Phase 1b study data for Luvelta in ovarian cancer, and Zymeworks' upcoming presentation of preclinical data on its antibody-drug conjugate programs.
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer
R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
Thinking on linkers for antibody-drug conjugates
Linker chemistry in antibody-drug conjugates (ADCs) plays a crucial role in cancer therapies, determining payload release and efficacy. Despite 11 FDA-approved ADCs and 266 clinical trials, the complexity of linkers remains a challenge, influencing ADC stability, toxicity, and target specificity. Innovations like PEG linkers and click chemistry aim to enhance ADC performance, but the field still lacks definitive rules for optimal linker design.
© Copyright 2025. All Rights Reserved by MedPath